JP7440989B2 - 2-[5-(3-クロロフェニル)-3-ヒドロキシピリジン-2-カルボニル]アミノ]酢酸を調製するための方法 - Google Patents
2-[5-(3-クロロフェニル)-3-ヒドロキシピリジン-2-カルボニル]アミノ]酢酸を調製するための方法 Download PDFInfo
- Publication number
- JP7440989B2 JP7440989B2 JP2020562673A JP2020562673A JP7440989B2 JP 7440989 B2 JP7440989 B2 JP 7440989B2 JP 2020562673 A JP2020562673 A JP 2020562673A JP 2020562673 A JP2020562673 A JP 2020562673A JP 7440989 B2 JP7440989 B2 JP 7440989B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- salt
- alkyl
- hydroxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024018279A JP2024054276A (ja) | 2018-05-09 | 2024-02-09 | 2-[5-(3-クロロフェニル)-3-ヒドロキシピリジン-2-カルボニル]アミノ]酢酸を調製するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862669135P | 2018-05-09 | 2018-05-09 | |
| US62/669,135 | 2018-05-09 | ||
| PCT/US2019/031310 WO2019217550A1 (en) | 2018-05-09 | 2019-05-08 | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024018279A Division JP2024054276A (ja) | 2018-05-09 | 2024-02-09 | 2-[5-(3-クロロフェニル)-3-ヒドロキシピリジン-2-カルボニル]アミノ]酢酸を調製するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523152A JP2021523152A (ja) | 2021-09-02 |
| JP2021523152A5 JP2021523152A5 (cg-RX-API-DMAC10.html) | 2022-07-22 |
| JP7440989B2 true JP7440989B2 (ja) | 2024-02-29 |
Family
ID=66625363
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562673A Active JP7440989B2 (ja) | 2018-05-09 | 2019-05-08 | 2-[5-(3-クロロフェニル)-3-ヒドロキシピリジン-2-カルボニル]アミノ]酢酸を調製するための方法 |
| JP2024018279A Pending JP2024054276A (ja) | 2018-05-09 | 2024-02-09 | 2-[5-(3-クロロフェニル)-3-ヒドロキシピリジン-2-カルボニル]アミノ]酢酸を調製するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024018279A Pending JP2024054276A (ja) | 2018-05-09 | 2024-02-09 | 2-[5-(3-クロロフェニル)-3-ヒドロキシピリジン-2-カルボニル]アミノ]酢酸を調製するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11713298B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3790863A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7440989B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20210006967A (cg-RX-API-DMAC10.html) |
| CN (1) | CN112088155A (cg-RX-API-DMAC10.html) |
| AR (1) | AR114886A1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2019265629B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3097219A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL278533B2 (cg-RX-API-DMAC10.html) |
| MX (2) | MX2020011845A (cg-RX-API-DMAC10.html) |
| TW (2) | TWI822776B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019217550A1 (cg-RX-API-DMAC10.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024054276A (ja) * | 2018-05-09 | 2024-04-16 | アケビア セラピューティクス インコーポレイテッド | 2-[5-(3-クロロフェニル)-3-ヒドロキシピリジン-2-カルボニル]アミノ]酢酸を調製するための方法 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ623002A (en) | 2006-06-26 | 2015-08-28 | Akebia Therapeutics Inc | Prolyl hydroxylase inhibitors and methods of use |
| NO2686520T3 (cg-RX-API-DMAC10.html) | 2011-06-06 | 2018-03-17 | ||
| TWI665190B (zh) | 2013-11-15 | 2019-07-11 | 阿克比治療有限公司 | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途 |
| WO2020075199A1 (en) * | 2018-10-12 | 2020-04-16 | Mylan Laboratories Limited | Polymorphic forms of vadadustat |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| US12612367B2 (en) | 2019-12-10 | 2026-04-28 | Akebia Therapeutics, Inc. | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative |
| CN112979541B (zh) * | 2019-12-17 | 2022-11-11 | 浙江大学 | 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用 |
| WO2021216530A1 (en) | 2020-04-20 | 2021-10-28 | Akebia Therapeutics, Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| CN111825606A (zh) * | 2020-06-17 | 2020-10-27 | 上海希迈医药科技有限公司 | 一种伐度司他晶型及其制备方法 |
| WO2022006427A1 (en) | 2020-07-02 | 2022-01-06 | Akebia Therapeutics, Inc. | Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat |
| GB202011431D0 (en) * | 2020-07-23 | 2020-09-09 | Johnson Matthey Plc | Polymorphs of vadadustat and methods for preparing the polymorphs |
| KR20240000649U (ko) | 2022-10-11 | 2024-04-18 | 성기봉 | 팥음료 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014522409A (ja) | 2011-06-06 | 2014-09-04 | アケビア セラピューティクス インコーポレイテッド | [(3−ヒドロキシピリジン−2−カルボニル)アミノ]アルカン酸、エステル及びアミドの製造方法 |
| CN105837502A (zh) | 2016-04-05 | 2016-08-10 | 湖南欧亚生物有限公司 | 一种Vadadustat的合成方法 |
| JP2018502882A (ja) | 2015-01-23 | 2018-02-01 | アケビア セラピューティクス インコーポレイテッドAkebia Therapeutics Inc. | 2−(5−(3−フルオロフェニル)−3−ヒドロキシピコリンアミド)酢酸の固体形態、その組成物及び使用 |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3655679A (en) | 1969-06-25 | 1972-04-11 | Merck & Co Inc | Certain aryl pyridine carboxylic acid derivatives |
| US3703582A (en) | 1970-04-20 | 1972-11-21 | Merck & Co Inc | Aryl pyridine carboxylic acids in the treatment of inflammation |
| US3894920A (en) | 1971-12-21 | 1975-07-15 | Sagami Chem Res | Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives |
| US4016287A (en) | 1972-07-17 | 1977-04-05 | Boehringer Ingelheim Gmbh | Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof |
| TW219933B (cg-RX-API-DMAC10.html) | 1990-02-26 | 1994-02-01 | Lilly Co Eli | |
| US5405613A (en) | 1991-12-11 | 1995-04-11 | Creative Nutrition Canada Corp. | Vitamin/mineral composition |
| TW352384B (en) | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
| DE4219158A1 (de) | 1992-06-11 | 1993-12-16 | Thomae Gmbh Dr K | Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| ATE149485T1 (de) | 1993-11-02 | 1997-03-15 | Hoechst Ag | Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel |
| EP0650961B1 (de) | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| CA2138929A1 (en) | 1993-12-30 | 1995-07-01 | Klaus Weidmann | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
| DE4410480A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE4410423A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US5789426A (en) | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| JPH09221476A (ja) | 1995-12-15 | 1997-08-26 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
| EP0900202A1 (de) | 1996-04-30 | 1999-03-10 | Hoechst Aktiengesellschaft | 3-alkoxypyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DE19650215A1 (de) | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| EP1024134A4 (en) | 1997-10-09 | 2003-05-14 | Ono Pharmaceutical Co | DERIVATIVES OF AMINOBUTANIC ACID |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| CA2325471C (en) | 1998-03-23 | 2010-08-17 | Aventis Pharmaceuticals Products Inc. | Piperididinyl and n-amidinopiperidinyl derivatives |
| US6159379A (en) | 1999-05-04 | 2000-12-12 | Baker Hughes Incorporated | Organic ammonium salts for the removal of water soluble organics in produced water |
| JP2001048786A (ja) | 1999-08-05 | 2001-02-20 | Yamanouchi Pharmaceut Co Ltd | 三環式ヘテロアリール誘導体 |
| US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
| US6849718B2 (en) | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
| US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| JP4590157B2 (ja) | 2001-03-21 | 2010-12-01 | アイシス イノヴェイション リミテッド | アッセイ、方法および手段 |
| SE0101327D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | New crystalline forms |
| US6566088B1 (en) | 2001-10-04 | 2003-05-20 | Board Of Regents, The University Of Texas System | Prolyl-4-hydroxylases |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| HU229475B1 (en) | 2001-12-06 | 2014-01-28 | Fibrogen | Methods of increasing endogenous erythropoietin (epo) |
| EP1556033A4 (en) | 2002-05-17 | 2006-05-31 | Celgene Corp | METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES |
| IL166426A0 (en) | 2002-08-29 | 2006-01-15 | Merck & Co Inc | N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| EP1554394B1 (en) | 2002-10-16 | 2009-12-16 | Isis Innovation Limited | Screening methods using a structural model of FIH |
| EP1567528A1 (en) | 2002-11-21 | 2005-08-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| WO2005007192A2 (en) | 2003-06-06 | 2005-01-27 | Fibrogen, Inc. | Cytoprotection through the use of hif hydroxylase inhibitors |
| CN103145616B (zh) | 2003-06-06 | 2015-09-30 | 菲布罗根有限公司 | 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途 |
| GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| WO2005108370A1 (ja) | 2004-04-16 | 2005-11-17 | Ajinomoto Co., Inc. | ベンゼン化合物 |
| AU2005250412B2 (en) | 2004-05-28 | 2009-09-17 | Fibrogen, Inc. | HIF prolyl hydroxylase activity assay |
| JP2008500951A (ja) | 2004-05-31 | 2008-01-17 | 田辺三菱製薬株式会社 | 二環化合物 |
| EA200700243A1 (ru) | 2004-07-14 | 2007-08-31 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения гепатита с |
| TW200616969A (en) | 2004-09-17 | 2006-06-01 | Tanabe Seiyaku Co | Imidazole compound |
| US20080213404A1 (en) | 2005-02-04 | 2008-09-04 | Johnson Randall S | Hif Modulating Compounds and Methods of Use Thereof |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| CN101849943A (zh) | 2005-06-06 | 2010-10-06 | 菲布罗根公司 | 使用HIFα稳定剂的改进的贫血治疗 |
| AU2006259352A1 (en) | 2005-06-15 | 2006-12-28 | Fibrogen, Inc. | Use of HIF 1alfa modulators for treatment of cancer |
| US20070154482A1 (en) | 2005-09-12 | 2007-07-05 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| WO2007047194A2 (en) | 2005-10-11 | 2007-04-26 | Dana-Farber Cancer Institute, Inc. | Methods for treating mitf-related disorders |
| AU2006326662B2 (en) | 2005-12-09 | 2011-07-28 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof |
| US20090023666A1 (en) | 2006-01-09 | 2009-01-22 | BTG plc | Modulators of Hypoxia Inducible Factor-1 and Related Uses |
| WO2007082899A1 (en) | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| JP4801451B2 (ja) | 2006-01-19 | 2011-10-26 | 株式会社日立ハイテクノロジーズ | 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法 |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| ITMI20060179A1 (it) | 2006-02-02 | 2007-08-03 | Abiogen Pharma Spa | Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse |
| US7625927B2 (en) | 2006-02-27 | 2009-12-01 | Alcon Research, Ltd. | Method of treating glaucoma |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| PE20071020A1 (es) | 2006-03-07 | 2007-12-11 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa |
| JP2009537558A (ja) | 2006-05-16 | 2009-10-29 | スミスクライン・ビーチャム・コーポレイション | プロリルヒドロキシラーゼ阻害剤 |
| TWI394747B (zh) | 2006-06-23 | 2013-05-01 | Smithkline Beecham Corp | 脯胺醯基羥化酶抑制劑 |
| NZ623002A (en) | 2006-06-26 | 2015-08-28 | Akebia Therapeutics Inc | Prolyl hydroxylase inhibitors and methods of use |
| TW200845994A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: prolyl hydroxylase inhibitors |
| CL2008000066A1 (es) | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
| ES2446418T3 (es) | 2007-04-18 | 2014-03-07 | Amgen, Inc | Derivados de indanona que inhiben la prolil hidroxilasa |
| WO2008130527A1 (en) | 2007-04-18 | 2008-10-30 | Merck & Co., Inc. | Novel 1,8-naphthyridine compounds |
| US8030346B2 (en) | 2007-05-04 | 2011-10-04 | Amgen Inc. | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity |
| EP2160187B1 (en) | 2007-05-16 | 2013-05-22 | Merck Sharp & Dohme Corp. | Spiroindalones |
| WO2008141731A2 (en) | 2007-05-18 | 2008-11-27 | Bayer Healthcare Ag | Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| CN101868251B (zh) | 2007-08-06 | 2012-10-10 | 千寿制药株式会社 | 含有HIF-1α和HIF-2α表达抑制物质的药物 |
| TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| US20110028507A1 (en) | 2007-08-10 | 2011-02-03 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| WO2009035534A2 (en) | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009043093A1 (en) | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Hif inhibition |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009067790A1 (en) | 2007-11-26 | 2009-06-04 | Uti Limited Partnership | STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION |
| JP2011505367A (ja) | 2007-11-30 | 2011-02-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| WO2009073497A2 (en) | 2007-11-30 | 2009-06-11 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
| EP2240178A4 (en) | 2007-12-19 | 2011-10-26 | Glaxosmithkline Llc | PROLYLHYDROXYLASEHEMMER |
| US20110003013A1 (en) | 2008-01-04 | 2011-01-06 | Garvan Institute Of Medical Research | Method of increasing metabolism |
| US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
| SI2268618T1 (sl) | 2008-03-03 | 2015-09-30 | Novartis Ag | Spojine in sestavki kot modulatorji aktivnosti TLR |
| WO2009117676A2 (en) | 2008-03-20 | 2009-09-24 | Forest Laboratories Holdings Limited | Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase |
| AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
| MX2011000656A (es) | 2008-07-23 | 2011-02-23 | Hoffmann La Roche | Compuestos heterociclicos antiviricos. |
| BRPI0913485A2 (pt) | 2008-09-15 | 2016-06-07 | Kasina Laila Innova Pharmaceuticals Private Ltd | medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres. |
| WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
| WO2010128355A2 (en) * | 2008-12-26 | 2010-11-11 | Actavis Group Ptc Ehf | Improved processes for preparing substantially pure arformoterol and its intermediates |
| BRPI1013432B1 (pt) | 2009-03-31 | 2019-12-17 | Kissei Pharmaceutical | derivado de indolizina e composição farmacêutica |
| CA2774039A1 (en) | 2009-11-06 | 2011-05-12 | Aerpio Therapeutics Inc. | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha |
| CN103717214A (zh) | 2011-06-06 | 2014-04-09 | 阿克比治疗有限公司 | 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物 |
| US20130022974A1 (en) | 2011-06-17 | 2013-01-24 | The Regents Of The University Of Michigan | Dna methylation profiles in cancer |
| CA2842730C (en) | 2011-07-22 | 2018-08-21 | Beijing Betta Pharmaceuticals Co., Ltd | Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| HUE066123T2 (hu) | 2013-06-13 | 2024-07-28 | Akebia Therapeutics Inc | Készítmények és módszerek anémia kezelésére |
| CA2921005A1 (en) | 2013-08-16 | 2015-02-19 | Ohio State Innovation Foundation | Compositions and methods for modulating dna methylation |
| TWI665190B (zh) | 2013-11-15 | 2019-07-11 | 阿克比治療有限公司 | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途 |
| RU2016133980A (ru) | 2014-01-23 | 2018-03-01 | Экебиа Терапьютикс, Инк. | Композиции и способы для лечения заболеваний глаз |
| MX2017008418A (es) * | 2014-12-30 | 2017-09-28 | Dow Agrosciences Llc | Picolinamidas con actividad fungicida. |
| AU2016235534A1 (en) | 2015-03-20 | 2017-10-12 | Akebia Therapeutics, Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
| CN106146491B (zh) * | 2015-03-27 | 2017-12-12 | 沈阳三生制药有限责任公司 | 被芳基或杂芳基取代的5‑羟基‑1,7‑萘啶化合物、其制备方法及其制药用途 |
| NZ735973A (en) | 2015-04-01 | 2023-06-30 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| CN111320577B (zh) | 2018-12-13 | 2023-06-23 | 广东东阳光药业有限公司 | 一种吡啶酰胺的制备方法及其应用 |
| PH12022551040A1 (en) | 2019-10-31 | 2023-05-29 | Akebia Therapeutics Inc | Therapeutic methods using vadadustat |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| AR121626A1 (es) | 2020-03-20 | 2022-06-22 | Akebia Therapeutics Inc | Compuestos inhibidores de phd, composiciones y métodos de uso |
| KR20220156890A (ko) | 2020-03-20 | 2022-11-28 | 아케비아 테라퓨틱스 인코포레이티드 | Phd 억제제 화합물, 조성물, 및 용도 |
| EP4121425A1 (en) | 2020-03-20 | 2023-01-25 | Akebia Therapeutics Inc. | Phd inhibitor compounds, compositions, and use |
-
2019
- 2019-05-08 US US17/053,614 patent/US11713298B2/en active Active
- 2019-05-08 TW TW108115898A patent/TWI822776B/zh active
- 2019-05-08 KR KR1020207035252A patent/KR20210006967A/ko not_active Ceased
- 2019-05-08 AR ARP190101226A patent/AR114886A1/es unknown
- 2019-05-08 WO PCT/US2019/031310 patent/WO2019217550A1/en not_active Ceased
- 2019-05-08 EP EP19725555.7A patent/EP3790863A1/en active Pending
- 2019-05-08 MX MX2020011845A patent/MX2020011845A/es unknown
- 2019-05-08 AU AU2019265629A patent/AU2019265629B2/en active Active
- 2019-05-08 CA CA3097219A patent/CA3097219A1/en active Pending
- 2019-05-08 TW TW112140875A patent/TWI926230B/zh active
- 2019-05-08 IL IL278533A patent/IL278533B2/en unknown
- 2019-05-08 JP JP2020562673A patent/JP7440989B2/ja active Active
- 2019-05-08 CN CN201980030849.4A patent/CN112088155A/zh active Pending
-
2020
- 2020-11-05 MX MX2024014558A patent/MX2024014558A/es unknown
-
2023
- 2023-06-13 US US18/334,101 patent/US12269802B2/en active Active
-
2024
- 2024-02-09 JP JP2024018279A patent/JP2024054276A/ja active Pending
-
2025
- 2025-03-05 US US19/071,033 patent/US20250243164A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014522409A (ja) | 2011-06-06 | 2014-09-04 | アケビア セラピューティクス インコーポレイテッド | [(3−ヒドロキシピリジン−2−カルボニル)アミノ]アルカン酸、エステル及びアミドの製造方法 |
| JP2018502882A (ja) | 2015-01-23 | 2018-02-01 | アケビア セラピューティクス インコーポレイテッドAkebia Therapeutics Inc. | 2−(5−(3−フルオロフェニル)−3−ヒドロキシピコリンアミド)酢酸の固体形態、その組成物及び使用 |
| CN105837502A (zh) | 2016-04-05 | 2016-08-10 | 湖南欧亚生物有限公司 | 一种Vadadustat的合成方法 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024054276A (ja) * | 2018-05-09 | 2024-04-16 | アケビア セラピューティクス インコーポレイテッド | 2-[5-(3-クロロフェニル)-3-ヒドロキシピリジン-2-カルボニル]アミノ]酢酸を調製するための方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020011845A (es) | 2021-01-15 |
| TWI926230B (zh) | 2026-05-21 |
| US11713298B2 (en) | 2023-08-01 |
| TWI822776B (zh) | 2023-11-21 |
| US12269802B2 (en) | 2025-04-08 |
| IL278533B1 (en) | 2025-10-01 |
| EP3790863A1 (en) | 2021-03-17 |
| JP2021523152A (ja) | 2021-09-02 |
| KR20210006967A (ko) | 2021-01-19 |
| CA3097219A1 (en) | 2019-11-14 |
| TW202406895A (zh) | 2024-02-16 |
| WO2019217550A1 (en) | 2019-11-14 |
| IL278533A (cg-RX-API-DMAC10.html) | 2021-01-31 |
| AU2019265629B2 (en) | 2024-09-12 |
| AU2019265629A1 (en) | 2021-01-07 |
| US20240158354A1 (en) | 2024-05-16 |
| US20210070709A1 (en) | 2021-03-11 |
| CN112088155A (zh) | 2020-12-15 |
| MX2024014558A (es) | 2025-01-09 |
| US20250243164A1 (en) | 2025-07-31 |
| AR114886A1 (es) | 2020-10-28 |
| IL278533B2 (en) | 2026-02-01 |
| TW201946903A (zh) | 2019-12-16 |
| JP2024054276A (ja) | 2024-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12269802B2 (en) | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino] acetic acid | |
| US10604490B2 (en) | Processes for preparing ASK1 inhibitors | |
| JP6189315B2 (ja) | 置換された5−フルオロ−1h−ピラゾロピリジン類を製造するための方法 | |
| TWI508956B (zh) | Preparation method of methylene disulfonate compound | |
| KR20160095161A (ko) | 포스파티딜이노시톨 3-키나제 억제제의 가공 방법 | |
| WO2022006427A1 (en) | Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat | |
| EP4013398B1 (en) | IMPROVED PROCESS FOR THE PREPARATION OF VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
| EP2401253B1 (en) | A process for the preparation of etoricoxib | |
| CN121362189A (zh) | 吉泊达星的中间体及其制备方法和吉泊达星的制备方法 | |
| KR20190044652A (ko) | 인돌 카르복스아미드 화합물을 제조하는 방법 | |
| KR20160118359A (ko) | 2-(아미노 에틸옥시) 벤조산 유도체의 고리화에 의한 3,4-디히드로-1,4-벤족사제핀-5(2h)-온 유도체의 제조 | |
| TWI545114B (zh) | 製備聯苯基咪唑化合物之方法 | |
| RU2833026C2 (ru) | Способ получения 2-[[5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино]уксусной кислоты | |
| JP7568642B2 (ja) | 置換2-[2-(フェニル)エチルアミノ]アルカンアミド誘導体の製造方法 | |
| KR19980081393A (ko) | 카바메이트를 사용하는 클로로케토아민 제조방법 | |
| JPH09221472A (ja) | α−シクロアルキルアルキル置換メタンアミン類の不斉合成方法 | |
| KR101144776B1 (ko) | 광학 활성 벤젠설폰아마이드 유도체의 제조방법 | |
| BR112021020595B1 (pt) | Processo de produção de derivados de 2-[2-(fenil)etilamino] alcanoamida substituídos | |
| NZ729685B2 (en) | Process for manufacturing pyrimidine sulfamide derivatives | |
| NZ729685A (en) | Process for manufacturing pyrimidine sulfamide derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220502 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220502 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20220713 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230413 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230516 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230726 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231012 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231212 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240117 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240117 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240209 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7440989 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |